Citation 85796

MIMAKI,Y: WATANABE,K: ANDO,Y: SAKUMA,C: SASHIDA,Y: FURUYA,S: SAKAGAMI,H:. (2001). FLAVONOL GLYCOSIDES AND STEROIDAL SAPONINS FROM THE LEAVES OF CESTRUM NOCTURNUM AND THEIR CYTOTOXICITY.. 64(1)

Citation Details

TitleFLAVONOL GLYCOSIDES AND STEROIDAL SAPONINS FROM THE LEAVES OF CESTRUM NOCTURNUM AND THEIR CYTOTOXICITY.
AuthorsMIMAKI,Y: WATANABE,K: ANDO,Y: SAKUMA,C: SASHIDA,Y: FURUYA,S: SAKAGAMI,H:
Year2001
Volume64
Issue1

Summary

Year: 2001

Journal: Unknown

Organisms and Their Experiments (1)

Cestrum nocturnum (SOLANACEAE)

Experiment #Pharmacology TypeWorktypesCompoundResults
1Not specified
VOUCHER SPECIMEN REPORTED FOR
NoneNone
2Not specified
UV SPECTRUM GIVEN FORMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
FLAVONOL,4'-5-DIHYDROXY-7-METHOXY: 3-O-[6-O-TRANS-3-5-DIMETHOXY-4-HYDROXY-CINNAMOYL-BETA-D-GLUCOPYRANOSYL] (1-2)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-6)]-BETA-D-GLUCOPYRANOSIDE
None
3
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
FLAVONOL,4'-5-DIHYDROXY-7-METHOXY: 3-O-[6-O-TRANS-3-5-DIMETHOXY-4-HYDROXY-CINNAMOYL-BETA-D-GLUCOPYRANOSYL] (1-2)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-6)]-BETA-D-GLUCOPYRANOSIDE
INACTIVE
4
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
FLAVONOL,4'-5-DIHYDROXY-7-METHOXY: 3-O-[6-O-TRANS-3-5-DIMETHOXY-4-HYDROXY-CINNAMOYL-BETA-D-GLUCOPYRANOSYL] (1-2)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-6)]-BETA-D-GLUCOPYRANOSIDE
INACTIVE
5Not specified
UV SPECTRUM GIVEN FORMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
FLAVONOL,4'-5'DIHYDROXY-7-METHOXY: 3-O-BETA-D-XYLOPYRANOSYL(1-2)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-6)]-BETA-D-GLUCOPYRANOSIDE
None
6
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
FLAVONOL,4'-5'DIHYDROXY-7-METHOXY: 3-O-BETA-D-XYLOPYRANOSYL(1-2)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-6)]-BETA-D-GLUCOPYRANOSIDE
INACTIVE
7
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
FLAVONOL,4'-5'DIHYDROXY-7-METHOXY: 3-O-BETA-D-XYLOPYRANOSYL(1-2)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-6)]-BETA-D-GLUCOPYRANOSIDE
INACTIVE
8Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
SPIROST-5-EN-3-BETA-OL,2-ALPHA-HYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
None
9
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,2-ALPHA-HYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
WEAK ACTIVITY
10
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,2-ALPHA-HYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
EQUIVOCAL
11Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
SPIROST-5-EN-3-BETA-OL,2-ALPHA-17-ALPHA-DIHYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
None
12
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,2-ALPHA-17-ALPHA-DIHYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
WEAK ACTIVITY
13
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,2-ALPHA-17-ALPHA-DIHYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
INACTIVE
14Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
SPIROST-5-EN-3-BETA-OL,2-ALPHA-HYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
None
15
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,2-ALPHA-HYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
ACTIVE
16
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,2-ALPHA-HYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
EQUIVOCAL
17Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
SPIROST-5-EN-3-BETA-OL,2-ALPHA-15-BETA-DIHYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
None
18
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,2-ALPHA-15-BETA-DIHYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
ACTIVE
19
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,2-ALPHA-15-BETA-DIHYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
WEAK ACTIVITY
20Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
SPIROST-5-EN-3-BETA-OL,2-ALPHA-17-ALPHA-DIHYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
None
21
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,2-ALPHA-17-ALPHA-DIHYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
WEAK ACTIVITY
22
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,2-ALPHA-17-ALPHA-DIHYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE 25(R):
EQUIVOCAL
23Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
SPIROST-5-EN-3-BETA-OL,3-O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[ALPHA-RHAMNOPYRANOSYL(1-4)-ALPHA-L-RHAMNOPYRANOSYL(1-4)]-BETA-D-GLUCOPYRANOSIDE 25(R):
None
24
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,3-O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[ALPHA-RHAMNOPYRANOSYL(1-4)-ALPHA-L-RHAMNOPYRANOSYL(1-4)]-BETA-D-GLUCOPYRANOSIDE 25(R):
WEAK ACTIVITY
25
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,3-O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[ALPHA-RHAMNOPYRANOSYL(1-4)-ALPHA-L-RHAMNOPYRANOSYL(1-4)]-BETA-D-GLUCOPYRANOSIDE 25(R):
WEAK ACTIVITY
26Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
SPIROST-5-EN-3-BETA-OL,2-ALPHA-HYDROXY: 3-O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[ALPHA-RHAMNOPYRANOSYL(1-4)-ALPHA-L-RHAMNOPYRANOSYL(1-4)]-BETA-D-GLUCOPYRANOSIDE 25(R):
None
27
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,2-ALPHA-HYDROXY: 3-O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[ALPHA-RHAMNOPYRANOSYL(1-4)-ALPHA-L-RHAMNOPYRANOSYL(1-4)]-BETA-D-GLUCOPYRANOSIDE 25(R):
ACTIVE
28
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-5-EN-3-BETA-OL,2-ALPHA-HYDROXY: 3-O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[ALPHA-RHAMNOPYRANOSYL(1-4)-ALPHA-L-RHAMNOPYRANOSYL(1-4)]-BETA-D-GLUCOPYRANOSIDE 25(R):
ACTIVE
Show SPARQL Queries (1)